Pharma Focus America

Complete Genomics Expands U.S. Operations with New Genomic Sequencing Manufacturing Facility in San Jose, California

Friday, May 24, 2024

Complete Genomics, a renowned genomic sequencing company, celebrated the opening of its new 10,115-square-foot manufacturing facility in San Jose, California. This facility marks the company's first U.S.-based supply chain hub, promising quicker delivery times for researchers using next-generation sequencing products for various conditions, including cancer, Alzheimer's, and obesity.

Complete Genomics highlighted the integration of supply chain resources from California, the U.S., and beyond, aiming to ensure efficient and reliable local supply assurance for American customers.

The newly inaugurated facility encompasses research and development, engineering, and ISO manufacturing operations, poised to accelerate the delivery of instruments to U.S. customers. The first DNBSEQ-G99* is expected to roll off the production line in the second quarter of this year, with Complete Genomics anticipating the completion and delivery of numerous DNBSEQ sequencers in 2024. Additionally, a 2,766-square-foot reagent manufacturing facility is slated to commence operations in 2025.

Dr. Radoje (Rade) Drmanac, Co-Founder and Chief Scientific Officer, emphasized the importance of local supply chains, especially in light of disruptions witnessed during the early stages of the Covid-19 pandemic, underscoring that the new facility will enhance support and customer experience.

The grand opening showcased state-of-the-art sequencers like the DNBSEQ-G800* and DNBSEQ-E25*, illustrating Complete Genomics' commitment to advancing genomic research. Established in 2005, the company has steadily expanded its footprint, culminating in its current 78,979 square foot location in San Jose.

Since the commercial launch of its DNBSEQ™ sequencing product line in August 2022, Complete Genomics has garnered recognition for its innovations. Notably, it received the 2023 R&D 100 Awards in the analytical testing category and the 2023 BioTech Breakthrough Awards' "Next Generation Sequencing Solution of the Year" for its DNBSEQ T20X2RS* ultra-high throughput sequencer, aimed at democratizing whole genome sequencing (WGS).

 

Source: prnewswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024